title: [Should we always use EGFR mutation analysis prior to palliative firstline therapy of metastatic adenocarcinoma of the lung? Pro].
authors.affiliation: Pneumologische Onkologie, Medizinische Klinik , Lungentumorzentrum Nürnberg. brueckl@klinikum-nuernberg.de
authors.forename: W
authors.initials: W
authors.lastname: Brückl
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics* / Q000556:secondary / Q000628:therapy*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000235:genetics*; D018773:Genes, erbB-1; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics* / Q000473:pathology / Q000628:therapy*; D009154:Mutation; D010166:Palliative Care; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors
chemical_list: D066246:ErbB Receptors; D011505:Protein-Tyrosine Kinases